ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Characteristics of patients with grade 3 neuroendocrine neoplasms in studies comparing grade 3 well to moderately differentiated neuroendocrine tumors and neuroendocrine carcinomas

Characteristics of patients with grade 3 neuroendocrine neoplasms in studies comparing grade 3 well to moderately differentiated neuroendocrine tumors and neuroendocrine carcinomas
Characteristic NET G-3 NEC
Number of patients, n (%) 89 (23)[1,2,3,4] 298 (77)[1,2,3,4]
Distribution of patients (%) 18 to 32[1,2,4] 68 to 79[1,2,4]
Age (median) 52 to 56[1,4] 55 to 64[1,4]
Primary tumor location (%)
Esophagus 0[1,2] 5 to 8[1,5]
Stomach 8 to 24[1,2] 7 to 8[1,5]
Pancreas 33 to 65[1,2,3] 13 to 25[1,3,5]
Colon-rectum 8 to 29[1,2] 24 to 32[1,5]
Small-bowel 0 to 5[1,2] 3 to 5[1,5]
Functional tumors (%) 14 to 25[1,3] 0 to 6[1,3,4,5]
Genetic syndrome 0 to 5[3,4] 0[3,4,5]
Stage IV (%) 62 to 100[1,3,4] 44 to 75[1,3,4]
Percentage of elevated plasma marker (CgA, NSE) CgA>NSE[3] NSE>CgA[3]
CgA (%) 42[3] 31[3]
NSE (%) 25[3] 50[3]
Uptake on 18-FDG PET/CT (%) 25 to 75[1,3] 19 to 89[1,3,5]
Uptake on somatostatin receptor scintigraphy (%) 88 to 92[1,3] 40 to 50[1,3]
Ki-67 (median, %) 21 to 40[1,2,3,4] 30 to 80[1,2,3,4,5]
Mitotic index 8 to 17[3,4] –
Necrosis (%) 42[3] 75 to 76[3,5]
Surgery of primary tumor (%) 60 to 83[1,3] 14 to 36[1,3,5]
Overall survival in months from diagnosis 41 to 99[1,3,4] 11 to 17[1,2,3,4,5]
NET G-3: well-differentiated grade 3 neuroendocrine tumor; NEC: neuroendocrine carcinoma; CgA: chromogranin A; NSE: neuron-specific enolase; 18-FDG: 18-fluorodeoxyglucose; PET: positron emission tomography; CT: computed tomography.
References:
  1. Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22:657.
  2. Scoazec JY, Couvelard A, Monges F, et al. Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality—The PRONETstudy group. J Clin Oncol 2012; 30(suppl):4129a.
  3. Vélayoudom-Céphise, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 2013; 20:649.
  4. Basturk O,Yang Z,Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39:683.
  5. Walter T, Tougeron D, Baudin E, et al. Characteristics, prognosis and treatments of 294 patients with poorly differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort. J Clin Oncol 2015; 33(suppl):4095a.

From: Coriat R, Walter T, Terris B, et al. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 2016; 21:1191. https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2015-0476. Copyright © 2016 Society for Translational Oncology. Reproduced with permission of John Wiley & Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: [email protected] or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (http://onlinelibrary.wiley.com).

Graphic 111374 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟